Forwardly’s Ligand Innovation Global Demonstrates LifeAir G1 Portable Ventilator at The Beverly Hills Lung and Sleep Institute
Forwardly, Inc. (OTCMKT: FORW) successfully demonstrated the LifeAir G1 Portable Ventilator at The Beverly Hills Lung and Sleep Institute, receiving positive feedback from doctors. The event allowed key personnel, including President George Sharp and Dr. Michael Soffer, to assess the product's operation. Ligand Innovation Global, Inc.'s CEO, Dr. Dayo Olakulehin, expressed cautious optimism for FDA submission by Christmas. The ventilator aims to provide low-cost alternatives for developing nations and is expected to significantly reduce emergency equipment costs.
- LifeAir G1 Portable Ventilator received positive feedback from medical professionals.
- Potential FDA submission for emergency use approval expected by Christmas.
- Partnership with Ligand IG aims to provide affordable ventilators.
- Risks associated with regulatory approval processes.
- Uncertainties in market acceptance and demand for new ventilator.
Henderson, NV, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Forwardly, Inc. (OTCMKT: FORW) announced today that a demonstration of the LifeAir G1 Portable Ventilator to doctors at The Beverly Hills Lung and Sleep Institute was very well received. It was also the first opportunity for Forwardly President, George Sharp, and Medical Board of Advisors Member, Dr. Michael Soffer, to observe the operation of the LifeAir G1 in person. The demonstration was orchestrated by Ligand Innovation Global, Inc.’s (“Ligand IG”) CEO, Dr. Dayo Olakulehin and Vice President of Global Sales, Abu Becker. Ligand IG is a partially owned company and partner of Forwardly
The protype was demonstrated to institute’s Dr. Dan Naim and Dr. Ashkan Naraghi both of whom expressed good impressions of Ligand’s achievements.
Dr. Soffer was also impressed with the ventilator’s progression and that the current iteration was developed within the budgetary restraints binding Ligand IG. “It is great that Forwardly and Ligand have the opportunity to work together to bring Dr. Olakulehin’s longtime dream of providing low cost ventilators to developing nations as well as making them economically feasible for mass stock piling by the industrial nations of the world, in preparation for any contingency”, he stated.
Following the demonstration, Dr. Olakulehin announced that Ligand is ‘cautiously optimistic” that it will complete its submission to the US FDA by Christmas for emergency use approval. “If not by Christmas, then certainly in January”, he exclaimed. Ligand has retained highly regarded law firm, Hogan Lovells US LLP, to represent the company to the FDA.
About Ligand Innovation Global, Inc.
Ligand IG continues development of the LifeAir G1 Emergency Portable Ventilator to address the expense of conventional ventilator systems which require the intubation and sedation of the patient. Ligand IG expects these units to become readily available, at a greatly reduced cost, to hospitals, nursing homes, and other sites where emergency, life-saving equipment, such as defibrillators are a necessity. Additional information regarding Ligand IG can be found at www.LigandGlobal.com.
About Forwardly, Inc.
Forwardly is an opportunity investor seeking to partner in fresh ideas. The company is headed by George Sharp, a longtime whistleblower, advocate against microcap fraud, and defender of shareholder rights. In addition to his continued participation in these activities, Mr. Sharp consults to public companies, attorneys and those associated with the financial markets. He is also a former consultant to OTC Markets Group, Inc. Further information about Forwardly, Inc. can be obtained through its website at www.ForwardlyPlaced.com
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Forwardly, Inc.
3535 Executive Terminal Drive
Suite 110
Henderson, NV 89052
702-840-4433
FAQ
What is Forwardly, Inc.'s stock symbol?
What recent demonstration did Forwardly conduct?
What are the expected outcomes for the LifeAir G1 Portable Ventilator?
When does Ligand IG expect to submit to the FDA?
